Uterine Fibroids Update for Pharmacists

摘要

Uterine fibroids are the most common benign neoplasms seen in premenopausal women. They place a significant burden on the U.S. economy, costing around $34 billion annually. Race, age, obesity, and family history are some of the main risk factors for the development of uterine fibroids. Older drug therapies for management include nonhormonal nonsteroidal anti-inflammatory drugs, tranexamic acids, levonorgestrel-releasing intrauterine system, and combined oral contraceptives. More recent therapies include the gonadotropin-releasing hormone agonists, gonadotropin-releasing hormone antagonists, and selective progesterone receptor modulators. Surgical procedures, endometrial ablation, and interventional radiology may be required in patients whose fibroids do not respond to drug therapy.